tiprankstipranks
Trending News
More News >
Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
US Market

Taysha Gene Therapies (TSHA) Stock Statistics & Valuation Metrics

Compare
1,026 Followers

Total Valuation

Taysha Gene Therapies has a market cap or net worth of $729.67M. The enterprise value is $630.17M.
Market Cap$729.67M
Enterprise Value$630.17M

Share Statistics

Taysha Gene Therapies has 261,530,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding261,530,400
Owned by Insiders16.18%
Owned by Institutions39.19%

Financial Efficiency

Taysha Gene Therapies’s return on equity (ROE) is -1.25 and return on invested capital (ROIC) is -67.24%.
Return on Equity (ROE)-1.25
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-67.24%
Return on Capital Employed (ROCE)-0.68
Revenue Per Employee114.15K
Profits Per Employee-1.22M
Employee Count73
Asset Turnover0.05
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Taysha Gene Therapies is -4.85. Taysha Gene Therapies’s PEG ratio is -1.56.
PE Ratio-4.85
PS Ratio0.00
PB Ratio13.65
Price to Fair Value6.05
Price to FCF-8.68
Price to Operating Cash Flow-9.00
PEG Ratio-1.56

Income Statement

In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.30M in profits. Earnings per share was -0.36.
Revenue8.33M
Gross Profit8.33M
Operating Income-91.46M
Pretax Income-89.30M
Net Income-89.30M
EBITDA-87.95M
Earnings Per Share (EPS)-0.36

Cash Flow

In the last 12 months, operating cash flow was -83.45M and capital expenditures -614.00K, giving a free cash flow of -84.06M billion.
Operating Cash Flow-83.45M
Free Cash Flow-84.06M
Free Cash Flow per Share-0.32

Dividends & Yields

Taysha Gene Therapies pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.92
52-Week Price Change-28.10%
50-Day Moving Average2.04
200-Day Moving Average1.96
Relative Strength Index (RSI)62.75
Average Volume (3m)4.38M

Important Dates

Taysha Gene Therapies upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date

Financial Position

Taysha Gene Therapies as a current ratio of 5.42, with Debt / Equity ratio of 31.04%
Current Ratio5.42
Quick Ratio5.42
Debt to Market Cap0.10
Net Debt to EBITDA0.86
Interest Coverage Ratio-896.66

Taxes

In the past 12 months, Taysha Gene Therapies has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Taysha Gene Therapies EV to EBITDA ratio is -4.06, with an EV/FCF ratio of -4.37.
EV to Sales42.83
EV to EBITDA-4.06
EV to Free Cash Flow-4.37
EV to Operating Cash Flow-4.39

Balance Sheet

Taysha Gene Therapies has $116.59M in cash and marketable securities with $61.35M in debt, giving a net cash position of -$55.24M billion.
Cash & Marketable Securities$116.59M
Total Debt$61.35M
Net Cash-$55.24M
Net Cash Per Share-$0.21
Tangible Book Value Per Share$0.29

Margins

Gross margin is 72.63%, with operating margin of -1097.55%, and net profit margin of -1071.62%.
Gross Margin72.63%
Operating Margin-1097.55%
Pretax Margin-1071.62%
Net Profit Margin-1071.62%
EBITDA Margin-1055.45%
EBIT Margin-1070.39%

Analyst Forecast

The average price target for Taysha Gene Therapies is $7.72, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.72
Price Target Upside168.06% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-48.97%
EPS Growth Forecast69.32%

Scores

Smart Score8
AI Score59
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis